Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$852.0m

Sana Biotechnology Valuation

Is SANA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SANA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SANA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SANA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SANA?

Other financial metrics that can be useful for relative valuation.

SANA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-2.6x
PEG Ration/a

Price to Book Ratio vs Peers

How does SANA's PB Ratio compare to its peers?

The above table shows the PB ratio for SANA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.4x
CGEM Cullinan Therapeutics
1.4x-13.1%US$920.1m
AVBP ArriVent BioPharma
3.2x14.3%US$933.4m
IGMS IGM Biosciences
7.3x7.7%US$823.9m
PRTA Prothena
1.6x25.1%US$902.4m
SANA Sana Biotechnology
2.6x-3.8%US$852.0m

Price-To-Book vs Peers: SANA is good value based on its Price-To-Book Ratio (2.6x) compared to the peer average (3.4x).


Price to Earnings Ratio vs Industry

How does SANA's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.6%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.6%
n/an/an/a
No more companies

Price-To-Book vs Industry: SANA is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.7x).


Price to Book Ratio vs Fair Ratio

What is SANA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SANA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SANA's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SANA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.99
US$12.50
+213.3%
22.5%US$15.00US$7.00n/a6
Oct ’25US$4.24
US$12.50
+194.8%
22.5%US$15.00US$7.00n/a6
Sep ’25US$6.05
US$12.50
+106.6%
22.5%US$15.00US$7.00n/a6
Aug ’25US$5.36
US$12.20
+127.6%
22.8%US$15.00US$7.00n/a5
Jul ’25US$5.47
US$12.20
+123.0%
22.8%US$15.00US$7.00n/a5
Jun ’25US$7.50
US$11.50
+53.3%
26.0%US$15.00US$7.00n/a6
May ’25US$9.63
US$11.50
+19.4%
26.0%US$15.00US$7.00n/a6
Apr ’25US$10.12
US$11.17
+10.3%
31.6%US$15.00US$5.00n/a6
Mar ’25US$11.27
US$10.50
-6.8%
31.5%US$15.00US$5.00n/a6
Feb ’25US$5.83
US$9.33
+60.1%
28.8%US$13.00US$5.00n/a6
Jan ’25US$4.08
US$8.80
+115.7%
30.0%US$13.00US$5.00n/a5
Dec ’24US$4.04
US$8.80
+117.8%
30.0%US$13.00US$5.00n/a5
Nov ’24US$3.09
US$9.20
+197.7%
27.0%US$13.00US$6.00n/a5
Oct ’24US$3.87
US$9.40
+142.9%
25.7%US$13.00US$6.00US$4.245
Sep ’24US$5.34
US$9.00
+68.5%
34.2%US$13.00US$6.00US$6.054
Aug ’24US$5.73
US$9.00
+57.1%
34.2%US$13.00US$6.00US$5.364
Jul ’24US$5.96
US$9.00
+51.0%
34.2%US$13.00US$6.00US$5.474
Jun ’24US$6.10
US$9.00
+47.5%
34.2%US$13.00US$6.00US$7.504
May ’24US$5.47
US$8.75
+60.0%
38.2%US$13.00US$5.00US$9.634
Apr ’24US$3.27
US$8.75
+167.6%
38.2%US$13.00US$5.00US$10.124
Mar ’24US$3.59
US$9.25
+157.7%
40.7%US$13.00US$5.00US$11.274
Feb ’24US$4.71
US$9.25
+96.4%
40.7%US$13.00US$5.00US$5.834
Jan ’24US$3.95
US$9.75
+146.8%
44.3%US$15.00US$5.00US$4.084
Dec ’23US$4.43
US$11.25
+154.0%
29.7%US$15.00US$6.00US$4.044
Nov ’23US$5.82
US$12.75
+119.1%
32.5%US$18.00US$7.00US$3.094
Oct ’23US$6.00
US$12.75
+112.5%
32.5%US$18.00US$7.00US$3.874

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies